(Total Views: 436)
Posted On: 09/25/2021 10:20:17 PM
Post# of 154858
isnt the off label mooted by the fact that there are no disease-specific patents as yet awarded?
in other words, all of cydy's disease-specific patents are as yet unawarded so the uspto 20 year clock is not yet begun?
i think this means that no generic leronlimab can be marketed for at least 20 years, rather than the fda 12 year limit (assuming the fda approved LL for covid today)?
in other words, all of cydy's disease-specific patents are as yet unawarded so the uspto 20 year clock is not yet begun?
i think this means that no generic leronlimab can be marketed for at least 20 years, rather than the fda 12 year limit (assuming the fda approved LL for covid today)?
(0)
(0)
